2-Methyl-3-butyn-2-ol → 10-(3-Methyl-3-Oxidanyl-But-1-Ynyl)-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepine-2-Carboxamide

HRID 575181Notes

Reaction equation

HRID 575181 reaction equation
Br[C:2]1[CH:3]=[CH:4][C:5]2[O:11][CH2:10][CH2:9][N:8]3[CH:12]=[C:13]([C:15]([NH2:17])=[O:16])[N:14]=[C:7]3[C:6]=2[CH:18]=1.[CH3:19][C:20]([CH3:24])([C:22]#[CH:23])[OH:21]>>[OH:21][C:20]([CH3:24])([CH3:19])[C:22]#[C:23][C:2]1[CH:3]=[CH:4][C:5]2[O:11][CH2:10][CH2:9][N:8]3[CH:12]=[C:13]([C:15]([NH2:17])=[O:16])[N:14]=[C:7]3[C:6]=2[CH:18]=1

Participants

3

Reactant 2

HCID 82582-Methyl-3-butyn-2-olHCID 6831288310-Bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide

Product 1

HCID 7171469410-(3-Methyl-3-Oxidanyl-But-1-Ynyl)-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepine-2-Carboxamide

Procedure

10-Bromo-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2-carboxamide (0.1 g) was reacted with dimethyl ethynyl carbinol similar to as described in Procedure E to afford 52.2 mg of 10-(3-hydroxy-3-methyl-but-1-ynyl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2-carboxamide following reverse phase hplc purification. MS (Q1) 338 (M)+. 1H NMR (400 MHz, DMSO) δ 8.50 (d, J=2.1 Hz, 1H), 7.79 (s, 1H), 7.51 (s, 1H), 7.29 (dd, J=8.5, 2.2 Hz, 1H), 7.11 (s, 1H), 7.01 (d, J=8.5 Hz, 1H), 5.42 (s, 1H), 4.48 (s, 4H), 1.48 (s, 7H).

Sources & evidence

ORD record
ord-f6a01ca418244e279e062e2b33f64a9e
Source dataset
uspto-grants-2015_05
Patent number
US09034866B2

Reaction notes

Loading…